Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIOD and BCRX I own but neither are in profit. Won't catch a falling knife. What a shame for BCRX they have had decent news from Japan but never could get past the shorts it's battling too much short interest. I am considering keeping BCRX, BIOD I am in the hole a few thousands dollars so just waiting for Canadian currency and price of BIOD to pick up right now or the Canadian currency to drop back the loss won't be so much if the American dollar rises. BIOD will end up in a spot for the trials and I see them diluting the shareholders for the money over getting partnership. FDA didn't exactly give BIOD a shining or half shining CRL. Biod knows it will be a hard road and the management kind of prove themselves to be not so bright. In maybe a few years or so it might be approved. Long term would have been between 3-6 months also but BIOD will be taking a bit longer unless partnership comes to their aid. JMHO
It's going to be awhile. Wish they would at least cover some of the short interest though. JMHO
Yes it will be. Such a shame for market to fall on such good news with china, India and some US stats. Bernanke better give what the markets wants. LOL GM says they will be setting out their financials and it's suppose to be good nothing that will beat Ford's. Let's see who rises to be KING of the North American automakers. JMHO
I have to agree. I feel they knew about this already on Friday and didn't buffer this instead of just releasing it they kept it thinking it might not be so bad. Most likely now they either have to find a partner to help with the trials or they dilute the stock. Didn't think it was going to be this bad the CRL at least a light one would have not been so bad.JMHO
Mosaic not bad next take-over target IMO. GM IPO tomorrow breaking news. LOL now the fun begins GM asking between 26-29 a share. Ford going to wipe their ass clean... No wonder why they went bankrupt. JMHO
They took India into account which should have been thrown out. The drug itself nothing was wrong with it. Figures FDA couldn't find their nose from their butt from the ground. Hoping at least now someone merges to help BIOD as they cannot go through that many more trials without financing or they will dilute the stock. JMHO
RBC targets it just for this year between 13-17 a PPS however that doesn't include approval or JV, take-out, sales of drugs etc etc. That is just for market cap. JMHO
It's all about timing in the market. You have to remember US elections, FEDS QE2, China just came out with great stats, Japan speculation on another stimulus right after the FEDS and oodles of more earnings and US data. This is a chalk full week with words from Eurozone data also and more China data coming and decision of POT and BHP battle and probably a lot more M/A in biotech sectors with the approvals given this week-end. We'll find out what FDA gave to BIOD. Ironic because if they do give approval Diabetes Week kicks off. JMHO
http://www.bloomberg.com/news/2010-11-01/china-s-manufacturing-growth-accelerates-more-than-estimates-in-october.html
http://www.nytimes.com/2010/11/01/business/01markets.html?src=busln
http://news.google.com/news/url?sa=t&ct2=us%2F0_0_s_1_2_aa&usg=AFQjCNFp-GOO2XXNjj6qFfLpTl1wm279tw&cid=8797611979857&ei=mTjOTOgHmcSUBKj4oaYD&rt=SECTION&vm=STANDARD&url=http%3A%2F%2Fin.reuters.com%2Farticle%2FidINIndia-52578820101101
http://news.google.com/news/url?sa=t&ct2=us%2F0_0_s_3_2_aa&usg=AFQjCNFQu-1txddLlg6z0XdPkfxD24CPzQ&cid=8797611174212&ei=mTjOTOgHmcSUBKj4oaYD&rt=SECTION&vm=STANDARD&url=http%3A%2F%2Fwww.bloomberg.com%2Fnews%2F2010-10-31%2Fjapan-s-bonds-may-rise-as-yen-s-gain-adds-pressure-on-boj-to-expand-easing.html
No sense to worry only found one article released today on BIOD. Looks like we will get ready to rumble and roll and see what happens tomorrow morning. JMHO
http://www.thestreet.com/story/10905957/1/fda-ends-october-with-drug-approvals.html?cm_ven=GOOGLEN
:) BHP will be upping the ante on POT rumors are hitting the mill since decision is just around the corner of FEDS meeting and elections. So if you hold POT catty keep holding because POT is looking for a fight and Klopper knows his job is on the line and he cannot afford to lose. JMHO
http://c.moreover.com/click/here.pl?x3625181976&f=1774
Ford Motor Company is Today's Focus Stock on MicroStockProfit.com
DALLAS, Oct. 27, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Ford Motor Company (NYSE: F). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/F
Ford Motor Company designs, develops, manufactures, and services cars and trucks worldwide. It operates in two sectors, Automotive and Financial Services.
The Company was founded in 1903 and is based in Dearborn, Michigan.
Message Board Search for F: http://www.boardcentral.com/boards/F
In the report, the analyst notes:
"Ford shares were higher as the auto giant's quarterly earnings came in above Wall Street's outlook. Net income for the third quarter rose 68% to $1.69 billion, or 43 cents a share, beating analysts' profit expectations of 36 cents a share. It was the Company's sixth straight quarterly profit. Ford attributed the strong quarterly performance to its strong products, momentum in North America and continued success at Ford Credit.
"Investors also welcomed the news that it would pay down its revolving credit line by $2 billion and use cash to fully prepay the remaining $3.6 billion of debt owed to the VEBA retiree health care trust. Ford's prepayment of the remaining $3.6 billion of debt is expected ..."
To read the entire report visit: www.microstockprofit.com/lp/F
See what investors are saying about F at http://www.stockhideout.com
Get breaking news on F at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: MicroStockProfit.com Brian Johnson 1-888-307-2850 info@microstockprofit.com
Too much speculation going on BIOD. I am just going to see pre-market bid and ask pretty much will tell all. BIOD might be halted too who knows, I'll know when they show no bid and ask in pre-market. Hopefully there will be something Monday morning or A/H. So far nothing on either approvals from the October 30 schedule nor today even though some releases on approvals showed up on Saturday. BIOD SO far is the only one without a release of any PR. No news anywhere that I can find on any website or google has a thing on BIOD's FDA decision they are keeping a tight lid. I would be nice if BIOD ended up like HGSI now that would be a kicker....LOL JMHO
It does have potential but right now everyone on pins and needles trying to speculate why no FDA listing out on BIOD since today was the decision. I am hoping even if partial approval would be all right with me and it would at least buffer the stock from the raging shorts. Full approval would be better. Interesting enough someone got approval today for diabetes I think it was NOVO there was news release about it all day then for some reason it was yanked from every news website, not sure why. It looks like BIOD may not announce anything until trading day Monday. I hope not better to know at least tomorrow so investors can judge for themselves and make decisions. No news is good news but also on flip side of the coin no news is frustrating because your mind goes in all directions as to is it bad, is it good.....I am just trying to be optimistic about it. BIOD could have at least released something to ease the minds of the investors if there was a delay or something. JMHO
Agreed :). Let GM chew on that when their IPO comes out they will have quick pop and like most IPO's this year went down less then their IPO. This is the second time I am on Ford. I didn't get in as cheap in but averaged out about 9 and cashed out last year at a bit over 13.00 I made a good chunk of change. A little down on FORD only because of the exchange rate currency since I am Canadian but got FORD up at a little over .98 on the dollar this time around but not worried about FORD. It is the least of my stocks I bother to look at when trading. I see FORD close to the mid 16.25-16.45 before GM IPO comes out. This time around I might see GM for quick trade only since they will list on the TSX also when the IPO comes out but I still have 5000 shares riding on FORD.
http://www.fool.com/investing/general/2010/10/30/fords-war-on-debt-continues.aspx
http://ca.autos.yahoo.com/p/2022/skid-masters-top-10-cars-for-winterspecial-feature
http://ca.autos.yahoo.com/p/2026/cars-that-lose-their-value-fastest
http://ca.autos.yahoo.com/p/2013/best-beaters-for-the-budget-minded
http://ca.autos.yahoo.com/p/2011/what-your-car-is-trying-to-tell-you
Things you would have never thought of in your car. Provided by Yahoo.ca Finance.
:) Trueheart.
Thanks Catty. I am a boredhousewife.:) I study all the time on stocks and markets even when the market is closed because news never sleeps. It will be quite interesting what FORD does in the next few weeks before GM launches it's IPO. I am sure the punches will be pulled out just in time for the elections and FED QE2. Now it becomes a race to see who will be top dog in the North American industry. Chrysler also is thinking of IPO sometime in mid 2011 and that could get even more interesting if all 3 automakers are back in the game. JMHO
It would just get more interesting. GM and FORD will go head to head. Both stocks should see massive volumes and when reports in the auto industry comes out and one or the other comes out on top will just drive the stock higher. I bet FORD has the upper advantage then GM anyway. GM may have a cleaner plate because of the bankruptcy but FORD has the upper hand in the profit margin and shares, while GM has to still pay the government back. Consecutive profits in earnings, almost debt free by end of the year and expansion in emerging market FORD is already there. GM has yet to show they can profit in quarters and sales against FORD. Shame auto stats out next week and GM's IPO not slated until November 11. It would have been totally fun to see on a day like auto sales data if who is the better honcho. Most analyst have already had their minds made up that FORD is the better horse. I think FORD stock will rise when the date of GM's IPO into the market again gets closer and then the fun begins. (don't forget shorts also have to cover)JMHO
http://www.gekkowire.com/?p=5365
An outlook on bulls and bears and if BIOD will have a chance of approval.
BioCryst's Partner Gets Nod For Pediatric Use Of Peramivir In Japan -Quick Facts
10/27/2010 6:28 AM ET
(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX: News ) said its partner, Shionogi & Co., Ltd., has received approval for an additional indication for use of intravenous peramivir to treat children and infants with influenza in Japan.
In January 2010, Shionogi received the world's first approval for i.v. peramivir and launched it under the commercial name RAPIACTA in Japan. It was initially approved for the treatment of adults with uncomplicated seasonal influenza, as well as those at high-risk for complications associated with influenza.
Shionogi has stated it intends to secure an adequate supply of RAPIACTA) to treat approximately 1 million people during the upcoming influenza season. In addition, Shionogi is taking steps to ensure its manufacturing capability and a stable supply to meet urgent demands.
Pretty close to where my level II quote stands somewhere around that slightly higher in the 7.25 range when approval is due. Shame I forgot October 30 lands on a Saturday so Friday should get interesting investors are either in or out that day and risk the approval. It's short interest is ridiculous on a lot of the BIOTECH stocks they should be creaming shorts soon. I am surprised that BIOD isn't on there considering it has more short interest than BCRX which I also own. It is crazy on on how many days these jerks get to cover. JMHO
Top 10 Biotech Stocks with Highest Short Interest: MATK, BCRX, XNPT, CADX, KERX, CHBT, CLDX, GTXI, GERN, INCY (Oct 26, 2010)
Below are the top 10 Biotechnology stocks with the highest short interest as a percentage of total shares outstanding, UPDATED TODAY before 4:30 AM ET. Short Squeeze and Short Covering can cause these stocks to rise sharply. One Chinese company (CHBT) is on the list.
Martek Biosciences Corp. (NASDAQ:MATK) has the 1st highest short interest in this segment of the market. Its short interest is 19.4% of its total shares outstanding. Its Days to Cover is 12.12, calculated as current short interest divided by average daily volume. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has the 2nd highest short interest in this segment of the market. Its short interest is 15.5% of its total shares outstanding. Its Days to Cover is 20.72, calculated as current short interest divided by average daily volume. XenoPort, Inc. (NASDAQ:XNPT) has the 3rd highest short interest in this segment of the market. Its short interest is 15.2% of its total shares outstanding. Its Days to Cover is 3.45, calculated as current short interest divided by average daily volume. Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) has the 4th highest short interest in this segment of the market. Its short interest is 15.1% of its total shares outstanding. Its Days to Cover is 36.58, calculated as current short interest divided by average daily volume. Keryx Biopharmaceuticals (NASDAQ:KERX) has the 5th highest short interest in this segment of the market. Its short interest is 14.9% of its total shares outstanding. Its Days to Cover is 4.27, calculated as current short interest divided by average daily volume.
China-Biotics Inc. (NASDAQ:CHBT) has the 6th highest short interest in this segment of the market. Its short interest is 14.8% of its total shares outstanding. Its Days to Cover is 9.37, calculated as current short interest divided by average daily volume. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has the 7th highest short interest in this segment of the market. Its short interest is 13.8% of its total shares outstanding. Its Days to Cover is 9.67, calculated as current short interest divided by average daily volume. GTx, Inc. (NASDAQ:GTXI) has the 8th highest short interest in this segment of the market. Its short interest is 13.6% of its total shares outstanding. Its Days to Cover is 26.58, calculated as current short interest divided by average daily volume. Geron Corporation (NASDAQ:GERN) has the 9th highest short interest in this segment of the market. Its short interest is 13.2% of its total shares outstanding. Its Days to Cover is 16.8, calculated as current short interest divided by average daily volume. Incyte Corporation (NASDAQ:INCY) has the 10th highest short interest in this segment of the market. Its short interest is 13.1% of its total shares outstanding. Its Days to Cover is 10.1, calculated as current short interest divided by average daily volume.
Provided by Google Finance.
Well hopefully BIOD gives us a treat on before Halloween is a nice piece of candy to look forward too. :) Well I guess we will know if price opens up nicely and if BIOD releases results on opening market. JMHO
Rumor Mill Sends Micron Shares Higher, Inspires Demand for Call Options
By Andrew Wilkinson and Caitlin Duffy|Oct 20, 2010, 3:51 PM|Author's Website
MU – Micron Technology, Inc. – Renewed rumors that the memory chip maker could be the target of a leveraged buyout by private equity investors looking to take the company private inspired an options feeding frenzy today. Micron’s shares responded to speculative musings by rising as much as 6.30% to an intraday high of $7.76. Just before 2:00 p.m. in New York trading, one big options market participant initiated a large-volume bullish spread in the April 2011 contract. The debit call spread serves to position the trader to benefit handsomely should buyout rumors wind up having some truth to them ahead of April expiration. The options strategist picked up 21,750 calls at the April 2011 $9.0 strike for a premium of $0.71 each, and sold the same number of calls at the higher April 2011 $11 strike at a premium of $0.27 a-pop. Net premium paid for the transaction amounts to $0.44 per contract. Thus, the investor is prepared to make money should Micron’s shares surge 21.65% over today’s high of $7.76 to exceed the effective breakeven point on the spread at $9.44 by expiration day next year. The trader may pocket maximum potential profits of $1.56 per contract if the chip maker’s shares jump 41.75% to trade above $11.00 by April expiration. Investors populating Micron options during the session exchanged more than 7.1 calls on the stock for each single put in play as of 3:25 p.m. in New York. A total of 146,615 option contracts have changed hands on Micron Technology with 35 minutes to go before the closing bell.
Yup since they are expecting approval from FDA at end of the month and their earnings due out on December 9. Should get interesting in the next few trading days since their short interest is about 17%. Hopefully they get approval and the shorts get creamed for it. JMHO
Quote Details
Printable VersionShow Me
Open 4.08 P/E Ratio (TTM) --
Last Bid/Size 3.95 / 1 EPS (TTM) -1.71
Last Ask/Size 3.96 / 14 Next Earnings 9 Dec 2010
Previous Close 4.04 Beta 1.85
Volume 689,552 Last Dividend --
Average Volume 1,003,843 Dividend Yield 0.00%
Day High 4.08 Ex-Dividend Date --
Day Low 3.84 Shares Outstanding 26.4M
52 Week High 6.25 # of Floating Shares 21.36926M
52 Week Low 3.22 Short Interest as % of Float 17.59%
Provided by RBC.
Biodel Inc. Welcomes Analyst Initiation; BIOD, NVO, SOMX
October 19, 2010 16:06
JMP Securities gave the Drug Manufacturers - Other industry some good news as it announced it has initiated coverage on one of its stocks.
Biodel Inc. (BIOD) [Chart - Analysis - News] was given a rating of Mkt Perform on Tuesday, October 19th---a positive sign for the stock that investors typically welcome. FYI, JMP Securities uses the following rating scale when analyzing stocks: Mkt Outperform, Mkt Perform, Mkt Underperform.
Biodel Inc. has an average analyst recommendation score of 2 and competes for investment dollars with Novo Nordisk A/S (NVO) [Chart - Analysis - News] and Somaxon Pharmaceuticals, Inc. (SOMX) [Chart - Analysis - News]---two other stocks in the Drug Manufacturers - Other industry that have average analyst recommendation scores of 3 and 1, respectively.
Analyst recommendations are averaged and scored using the following rating scale:
- 1.0 = Strong Buy
- 2.0 = Buy
- 3.0 = Hold
- 4.0 = Sell
- 5.0 = Strong Sell
Why are Upgrades and Initiations Good and Downgrades Bad?
One event that is almost certain to get a reaction from Wall Street is an analyst upgrade or downgrade. Everyone is looking for an edge in the stock market, and quite often, traders turn to stock analysts to get that edge.
Upgrades and coverage initiations are typically good for stocks because they show that analysts either believe that the stock is going to perform better in the future or that the stock is worth covering and providing analysis on.
Downgrades are typically bad for stocks because they show that analysts believe that the stock is going to perform worse in the future.
What is a Stock Analyst?
Check out the Understanding Stock Analyst Research and Recommendations video and article for more info.
A stock analysts is a person---typically employed by a large bank, investment firm or analysis company---who devotes his/her life to learning and making predictions about a company and its future performance.
Stock analysts sift through company reports and filings, talk to company management, probe customers and competitors and basically do whatever they can to find out if a company is healthy and growing or sick and shrinking. Because this is incredibly demanding work, stock analysts typically only monitor one or two companies at a time.
Provided by Learning Markets
Intel to invest in US chip plants
Tue Oct 19, 1:48 PM
* Email Story
* IM Story
* Printable View
NEW YORK (AFP) - Intel Corp. announced plans on Tuesday to invest up to eight billion dollars in its US manufacturing facilities to produce next-generation computer chips.
Intel said the investment of six billion dollars to eight billion dollars over the next several years will fund deployment of its 22-nanometer (nm) chip manufacturing process across several existing US factories.
It will also fund construction of a new fabrication plant, known as a "fab," in the northwestern state of Oregon, Intel said in a statement.
Intel, the world's largest computer chip maker, is to begin production of its first 22nm microprocessors, codenamed "Ivy Bridge," in late 2011.
Intel said the projects will support 6,000 to 8,000 construction jobs and result in the creation of 800 to 1,000 new permanent high-tech jobs.
"The most immediate impact of our multi-billion-dollar investment will be the thousands of jobs associated with building a new fab and upgrading four others, and the high-wage, high-tech manufacturing jobs that follow," Intel president and chief executive Paul Otellini said.
Otellini said the investment demonstrates the Santa Clara, California-based company's "commitment to invest in the future of Intel and America."
"Contrary to conventional wisdom, we can retain a vibrant manufacturing economy here in the United States by focusing on the industries of the future," said Brian Krzanich, senior vice president of Intel's manufacturing and supply chain.
In February 2009, Intel announced seven billion dollars in state-of-the-art upgrades to its 32nm manufacturing facilities in the United States.
While three-fourths of Intel's revenue is generated overseas, the company said three-fourths of Intel's microprocessor manufacturing is located in the United States.
Intel said the new plant in Oregon is scheduled to begin research and development in 2013. It said the investment will also be used to upgrade two existing factories in Arizona and two existing facilities in Oregon.
With one million personal computers shipping per day, Intel said the upgrades will create the manufacturing capacity to allow for continued growth of the PC market and to address growing sectors such as mobile computing.
"Intel makes approximately 10 billion transistors per second," Krzanich said. "These investments will create capacity for innovation we haven't yet imagined."
Intel shares were up 0.73 percent to 19.33 dollars in early afternoon trading on Wall Street.
TheStreet.com
10 U.S. stocks that could double amid QE2
Boston— TheStreet.com
Published Monday, Oct. 18, 2010 4:01PM EDT
Quantitative easing - the government buying securities to support the economy - looks more certain by the day. Stocks may rally if so-called QE comes to pass. Investors ought to consider purchasing riskier stocks because they typically would rise more than the broader market. Here are 10 candidates predicted by analysts to double or triple in the next 12 months. They're ordered by their projected return, from big to biggest.
More related to this story
* Five U.S. stocks to buy, then hold for a decade
* 10 overpriced U.S. stocks actually worth buying
* Buffett's investment hand turns cold
10. Gannett Inc. (GCI-N12.47-0.38-2.96%) publishes newspapers, including USA Today, operates broadcasting stations and manages web sites. Second-quarter profit nearly tripled to $195-million, or 73 cents a share, as revenue declined 1.6 per cent to $1.4-billion. The operating margin rose from 15 per cent to 20 per cent. Gannett's stock trades at a trailing earnings multiple of 6, a forward earnings multiple of 5.4, a book value multiple of 1.6 and a cash flow multiple of 3.3 - 74 per cent, 82 per cent, 58 per cent and 80 per cent discounts to media peer averages. Around 75 per cent of analysts rate the stock "buy" and 25 per cent rank it "hold."
Bullish Scenario: Noble Financial predicts that Gannett's stock will double to $27.
9. Micron Technology Inc. (MU-Q7.54-0.07-0.93%) makes semiconductors. Micron swung to a fiscal fourth-quarter profit of $342-million, or 32 cents a share, as revenue surged 91 per cent to $2.5-billion. The operating margin turned positive. Micron's stock sells for a trailing earnings multiple of 3.8, a forward earnings multiple of 6, a book value multiple of 0.9, a sales multiple of 0.8 and a cash flow multiple of 2.3 - 82 per cent, 54 per cent, 84 per cent, 75 per cent and 84 per cent discounts to semiconductor industry averages. Of analysts following Micron, 14 rate its stock "buy", nine rate it "hold" and just one ranks it "sell."
Bullish Scenario: Raymond James Financial RJF-N forecasts that Micron's stock will rise 138 per cent to $18.
8. Entegris (ENTG-Q5.220.050.97%) sells integrity-management products to semiconductor, fuel-cell and life-sciences companies. It swung to a second-quarter profit of $18-million, or 14 cents a share, from a year-earlier loss. Revenue more than doubled. The operating margin climbed from the negatives to positive 16 per cent. The stock trades at a forward earnings multiple of 6.7, a book value multiple of 1.6 and a cash flow multiple of 9.5 - 49 per cent, 70 per cent and 36 per cent discounts to industry averages. Five analysts advise purchasing Entegris shares, two recommend holding and one says to sell.
Bullish Scenario: Craig-Hallum Capital values the stock at $10, suggesting a return of 114 per cent.
7. Orbital Sciences Corp. (ORB-N15.440.171.11%) develops rockets and space systems for commercial and military customers. Second-quarter profit contracted 27 per cent to $6.4-million, or 11 cents a share, as revenue expanded 25 per cent to $338-million. The operating margin narrowed from 4.8 per cent to 4.1 per cent. Orbital's stock sells for a forward earnings multiple of 13, a book value multiple of 1.6 and a sales multiple of 0.7 - 12 per cent, 68 per cent and 38 per cent discounts to aerospace and defense industry averages. All eight researchers covering Orbital Sciences advocate purchasing its shares.
Bullish Scenario: FBR Capital Markets expects Orbital's stock to double to $30.
6. AMR Corp. (AMR-N6.380.121.92%) owns American Airlines. The company's second-quarter loss narrowed 97 per cent to $11-million, or 3 cents a share, as revenue gained 16 per cent to $5.7-billion. The operating margin climbed from negative territory to positive 3.5 per cent. AMR's stock trades at a sales multiple of 0.1 and a cash flow multiple of 2 -- 91 per cent and 59 per cent discounts to airline peer averages. Of analysts following AMR, eight, or 57 per cent, rate its stock "buy", five rate it "hold" and one ranks it "sell." A median price target of $10.06 suggests 60 per cent of upside. Deutsche Bank offers a $14 target.
Bullish Scenario: Barclays forecasts that AMR's stock will more than triple to $20.
5. Clinical Data Inc. (CLDA-Q18.200.100.55%) is a biotechnology company. It has several late-stage compounds, including Vilazodone for depression and Stedivaze for cardiac stress. It also sells genetic tests to determine drug response. Its fiscal first-quarter loss narrowed to $14-million, or 51 cents a share, from a loss of $15-million, or 88 cents, a year earlier. Revenue grew 48 per cent. Clinical Data's stock is expensive based on all relative valuation metrics since the company is consistently unprofitable. Still, all six analysts following Clinical Data recommend purchasing its shares.
Bullish Scenario: McNicoll Lewis & Vlak values the stock at $37, suggesting that it will double.
4. Gleacher & Co. (GLCH-Q2.110.062.93%) is a boutique investment bank. It swung to a second-quarter loss of $5.2-million, or 4 cents a share, from a year-earlier profit. Revenue tumbled 41 per cent to $57-million. The operating margin fell into negative territory. Gleacher's stock trades at a trailing earnings multiple of 7.5, a forward earnings multiple of 6.8, a book value multiple of 0.7 and a sales multiple of 0.7 - 48 per cent, 59 per cent, 61 per cent and 71 per cent discounts to capital markets peer averages. Two analysts rate it "buy" and three rank it "hold." A median target of $4.17 suggests 132 per cent upside.
Bullish Scenario: KBW predicts that Gleacher's stock will soar 176 per cent to $5.
3. GSE Systems Inc. (GVP-A3.610.092.56%) sells simulation and other software to nuclear power, electric utility and chemical companies. Its second-quarter profit fell 35 per cent to $370,000, or 2 cents a share, as revenue gained 11 per cent to $12-million. The operating margin extended from 6.2 per cent to 7.4 per cent. GSE's stock sells for a forward earnings multiple of 11, a book value multiple of 1.6 and a sales multiple of 1.4 - 58 per cent, 68 per cent and 93 per cent discounts to software industry averages. All four analysts following GSE advise purchasing its shares. A median target of $8.15 suggests a 141 per cent return in 12 months.
Bullish Scenario: Benchmark Company values GSE's stock at $9, implying 172 per cent upside.
2. Avanir Pharmaceuticals (AVNR-Q3.23----%) acquires, develops and commercializes therapeutics. Avanir's fiscal third-quarter loss expanded 15 per cent to $5.7-million, but the per share loss remained steady at 6 cents due to dilution. Revenue fell 17 per cent to $490,000. The operating margin fell further into negative territory. Avanir has $41-million of cash and no debt. Its stock sells for a book value multiple of 10 and a sales multiple of 79 - sizable premiums to pharmaceutical industry averages. All four of the analysts evaluating Avanir recommend purchasing its shares.
Bullish Scenario: Jefferies predicts that Avanir's stock will triple to $10.
1. OncoGenex (OGXI-Q18.750.613.36%) is a biopharmaceutical company developing therapies for cancer. It swung to a second-quarter profit of $150,000, or 2 cents a share, from a loss of $4.6-million, or 82 cents, a year earlier. Revenue turned positive. OncoGenex has $48-million of cash and $1.3-million of debt. Its stock trades at a sales multiple of 2.9 and a cash flow multiple of 3.6 - 97 per cent and 80 per cent discounts to peer averages. All eight researchers covering OncoGenex rate its stock "buy." A median target of $48.17 suggests the stock will more than triple in 12 months.
Bullish Scenario: Rodman & Renshaw expects the stock to quadruple to $58.
Interesting stock tried to find it on Canadian Stock exchange but couldn't it only trades in US considering it is stationed here in Ontario. BNN has a clip today on what the company is doing and what they are doing. I do not own the stock as I haven't seen it trade yet as I am considering it. I do see it has done a stock split recently. The volume seems very low. I am actually surprised this stock is trading a bit low considering what it is doing with Merck and there maybe bio-tech companies that might be interested when they can approve their machine to test for heart attacks. I can also post for the posters what CNGH does and it's specs.JMHO
BNN Afterhours
5:30 PM Dr. Yahia Gawad
CEO
Cardiogenics
Focus: Heart attacks remain a leading cause of death and a big strain on the health care system. BNN sits down with Dr. Yahia Gawad, CEO, Cardiogenics a Canadian biotech looking to change that with a non-invasive heart attack test that would reduce wait times from over two hours to ten minutes.
Coming Up:
After Hours : August 16, 2010 : Advanced Heart Attack Diagnostics [08-16-10 5:20 PM]
One Canadian company is developing a technology to reduce the heart attack diagnostic process from an average of 2.8 hours to 15 minutes. BNN interviews Dr. Yahia Gawad, CEO, Cardiogenics.
Quote DetailsPrintable VersionShow MeOpen 0.42 P/E Ratio (TTM) --
Last Bid/Size 0.40 / 50 EPS (TTM) -0.83
Last Ask/Size 10.00 / 5 Next Earnings --
Previous Close 0.42 Beta 1.00
Volume 15,000 Last Dividend --
Average Volume 75,979 Dividend Yield 0.00%
Day High 0.42 Ex-Dividend Date --
Day Low 0.42 Shares Outstanding 24.6M
52 Week High 7.40 # of Floating Shares 49.61964M
52 Week Low 0.12 Short Interest as % of Float
52 Week Range Market Cap Sector/Industry
0.12 - 7.40 10.3M Technology/Scientific & Technical Instr.
Though CGNH has outperformed its Scientific & Technical Instr. peers over the last three months, over the past year it has lagged behind its peers.
Company DescriptionCardioGenics Holdings Inc., formerly JAG Media Holdings, Inc. is engaged in the development of products, targeting the immunoassay segment of the point-of-care (POC) in vitro diagnostic (IVD) testing market. The Company is focused on developing diagnostic test products to the IVD market. The Company's QL Care Analyzer (QLCA) is an automated point-of-care immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. Each cartridge is pre-loaded with the Company's beads, which have been coated with specific bind reagents and bioluminescent proteins linked to the target marker. A drop of whole blood added to the Cartridge creates the chemiluminescent reaction needed to deliver test results. It has developed four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. On July 31, 2009, it acquired CardioGenics Inc. (CardioGenics).
Growth
Investors need to know how much goods or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. In general, look for companies that sell and earn more than peers.
Net Profit Margin
293%
-137,131.00%-76,722%Insufficient data on CGNH for analysis of Net Profit Margin.
Earnings per Share Growth (TTM)
17,766%
-763.03%-961%EPS growth at CGNH is improving and is above the industry average. In addition there was no clear trend in EPS at CGNH over the last five years. The most recent EPS was -0.8327, a decrease of -763.03% over the previous year.
Sales Growth
8,313%
-2,200%Insufficient data on CGNH for analysis of Sales Growth.
Income Growth
2,717%
-2,038.03%-2,038%There was no clear trend in income growth at CGNH over the last five years.
Fundamentals
How is the company’s financial health?
When assessing the financial health of a company be aware that it is most relevant to compare the company against its peers as most ratios vary by industry. In addition, rarely will one ratio or statistic alone provide enough insight into the company to form and informed opinion.
Price/Earnings Ratio (TTM)
151.9x
0.2xInsufficient Price Earnings data on CGNH.
Price/Book (MRQ)
0.0x
14.8x1,087.0xLast quarter the Price to Book ratio at CGNH was 14.8x.
Return on Equity (TTM)
93%
-1,896%CGNH has a ROE of -114.99%
Total Debt/Total Capital (MRQ)
238%
0.00%0%CGNH uses little or no debt in its capital structure and may have less financial risk than the industry aggregate.
Provided by RBC
It did get volume but INMHO MM's head faked this the last few days. To generate volume the stock fell below the support line rose and then fell fast today. So hoping that the financial's show something soon. Natural gas fell among the commodities and about the only one that wasn't up. Looking bearish for energy stocks if the winter is not cold. El nino this year and doesn't look good for natural gas or energy stocks. They might have a short rally in December and January is my guess and not do much for the rest of the year. Oil is still doing good. I was hoping the company would announce some sort of PR before the earnings. It's been quite a long time now and they haven't said boo. I have contacted the company 3 weeks ago and still no reply from them. I would at least like to see this stock past .0020 and stay above it.
That is what I hear the earnings are coming out November 16. I hope they file on time and not delay.
I haven't sold because I am in the hole with it. I would not average down on this even when I was in the hole less on PKPL it is not worth it. I won't sell for a loss either. One thing I learned that sooner or later MM's will let it up again and when it does PR or promotes by the promoters it will go back up no matter what the market is at the time. OTCB stocks really do not move with the market like the higher exchanges they move like I said on PR's and momoteum. I am patient enough to let this one be until I get at least even keel with it, I am not missing the money and don't need it so why take a loss when there is a chance in the end of the year to next year that it will either be even or profit. I have 100,000 shares in this and if PKPL even hits in the .0065 range I am even. No sense in taking a loss when there is most likely a chance it will get back there in time and when the economy starts to become a bull market once again by next year stocks will start to move a little more stably.
Flippers before the forward split and after for sure dumped the stock not up to including the MM's who hold this stock. I do not see the stock being shorted it hasn't landed on the SHO list. Most of these penny stocks after the F/S declines. That is why PKPL needs a press release of some sort to update shareholders of the joint venture or earnings something is better than nothing to move the stock. Otherwise it would be the MM's who are the ones playing the stock not retails at this point. PKPL would move up fast if retail does hit upon it. It is losing it's support at .0018 though it's volume has picked up not a good sign INMHO.
I live in Canada. British Columbia. I did play the forward split on this one and this one did not do what a normal F/S split did. It did quite poorly with the disorganization of the company and under debt. Oilsands is hot but not yet until the oil prices reaches above the 80 dollar barrel mark and the shale is a good play but not for a bit and the natural gas factor depends on what the stockpile is and so far they are still overstocked. The outstanding shares of this company is too high and added on the A/S since the forward split. This stock will be under the MM's thumb until then or until retail investors put more pressure on this stock. OTCB needs promotion or press releases to actually move, as all penny stocks move by that momentum. It is about supply and demand and so far natural gas in not in demand yet. This company if lucky will be a target takeover INMHO. Canada oil sands is either going to eat up the junior companies or the Chinese will take out the juniors or make a buy play with the bigger companies. This stock did not move with the market and the owners of this company have not updated anything so makes this stock right now iffy, as to why they did a forward split. This stock may realize it's value maybe 3-5 years from now if they can stay their head above water in this economy. I do not intend to keep this one long considering how the company seems to be disorganized. I would not be surprised they will have a late filing for this quarter. I have better shale plays and natural gas that do higher than what PKPL does and they are not junior companies. Am I interested in the company at first yes now not so sure with how they run the company so far.
Company Description
Park Place Energy Corp. is an exploration-stage company. The Company is engaged in the exploration of oil and natural gas. The Company holds exploration interests in a property in Tennessee, United States. Its wholly owned subsidiary, Park Place Energy (Canada) Inc., holds the exploration interests in five properties in the provinces of British Columbia and Alberta, in Canada. In addition, on July 24, 2008, its subsidiary, Park Place Energy (Canada) Inc., acquired an interest in certain five year Northern Petroleum and Natural Gas Leases located in Alberta, Canada. In July 2008, the Company divested its entire interest in the six diamond concessions.In March, 2008, the Company acquired a 51% interest in five diamond concessions in Central Brazil. On April 1, 2008, it acquired a sixth diamond concession in Central Brazil consisting of 356.25 hectares.
3 Month: -57.4468
6 Month: 100
1 Year: -33.3333
Data as of 30 Oct 2009
Next: Performance
Shares Outstanding 673.0M
# of Floating Shares 66.7M
Telephone (403) 260-5375
Fax (403) 266-5657
Website www.parkplaceenerg...
Address 840-6th Avenue S.W.
Suite 300
Calgary, AB
T2P 3E5
Key Executives
CEO David Johnson
Treas. Tom Mayenknecht
(If anyone wants to contact them)
Net Profit Margin:Over the last twelve months operating margin at PKPL was -308.62%.
Earinings Per Share Growth(TTM)- most recent EPS was -0.0427.
Sales Growth-263%
-73.39%
-86%
Though the industry is experiencing positive sales growth as a whole, PKPL has been unable to grow sales and is losing market share. This trend continues from the previous year when sales growth at PKPL and the Oil & Gas - Integrated industry were -73.39% and -48.90%, respectively.
Earnings Growth- Income growth at PKPL was -19.82%.
Price Book-PKPL appears undervalued with one of the lowest Price to Book ratios in the Oil & Gas - Integrated sector at 24.2x, up 272.62% from last year's ratio of 0.1x.
Return on Equity (TTM)
172%
-170.72%
-446%
PKPL is not profitable and therefore has a negative ROE that is not meaningful.
Total Debt/Total Capital (MRQ)- PKPL's debt to total capital ratio, at 6.38%, is in-line with the Oil & Gas - Integrated industry's norm.
Performance of this stock for 2009 may reach a .01 by end of year.
Provided by RBC(Royal Bank)
Problem NITE needs to be knocked out and we need retail pressure to do that. As long as NITE sits on ask and bid it will be a game of chicken. Right now I expect they will head fake sometime this week to generate volume the lower the volume falls the less these MM's will get in profit. PKPL should have at least updated the shareholders of what they are up to instead of keeping silent it only pressures shareholders to sell and very little other retail investors to look at PKPL just by the way the MM's are screwing with the stock. So far PKPL did a very poor job of the forward split and not a word since of the joint venture nor other press releases. So far there is no promotion for this stock as well as no press releases. If it breaks away from the .0018 downwards then this stock is in trouble until the boys who own this company release a press release. Even if it does rise PPL who have been in this stock before forward split will be dumping shares again and so will the MM's puts this stock down again.
It would be nice if they just release something. There hasn't been anything for PR's since the forward split. So far PKPL has not moved with the market. Lucky for it didn't decline further when the market turned sour last week. Their volume has been below average for the last few trading days and the MM's are manipulating this thing to no end. Hopefully they are gonna release their earnings on time and not delay as natural gas and energy sectors are starting to gear up for the winter months and natural gas staying above 5.
I tried contacting them yesterday my email got bounced back twice. It is marc@catalystresearch.com is what NF energy investor relations is. I find it quite fishy the stock continues to decline dramatically considering the good PR's, as of late. Not one word about the up-listing and the MMs screwing the stock bids and asks spreads ridiculous and then up .10-25 cent spreads and then stock goes up .01 spreads. It is all over the place and every ask hit so far brings the bid down at a larger spread. So far haven't been able to reach Marc Robins is the rep's name and I am sure they probably have a lot of peed off investors contacting them. I am down half my investment since getting in after the R/S so not selling until something breaks so far not looking good. Until they announce something or their financials suppose to come out on November 12 I think. Let me know if you get a hold of the rep for NFEC.
No not yet and disappointed this should have already been on the AMEX considering the last Chinese companies recently who did a small R/S split recently reached the AMEX and NASDAQ easily in two weeks it has been close to over 2 months for this company since the upgrade announcement and still no up-listing. I have had spoken to the rep for the company and this is what he said.
Mr. Kim.
Sorry it has taken so long to respond. I've been waiting for either a
response from the AMEX or more news from NFEC to write a new report. I
just discovered that China was "closed" this week for a holiday of some
sort so I've been not able to really get much info for a write-up.
I have to say the only real problem with NFEC and the listing is
bureaucratic. All the problems are cleared up. It a process of stamping
the tickets and since the new york stock exchange has taken over the AMEX
it has become more structured.
I am also a little unhapply that the Company came out with such a
conservative projection of numbers. that was really hurtful being too
restrained. But this will pass as well.
Also, it doesn'r hurt to have the stock rest at this time.
I think he is full of it as other Chinese stocks have had no trouble up-listing in a short amount of time after an announcement of upgrading like UTA, GRUS etc. No way it should have taken this long and they did not have everything setup properly or right in the first place before announcing upgrade. They have great PR releases which do nothing for this company and each time it falls worse even with PR.
Hi elcheepo no biggie live in British Columbia and still another day of rain. I love to play in US stocks since our dollar almost at parity is the reason why I pick up stocks on US side and when the US dollar gets back up if and when it does the stocks I buy from the US worth more. I own Ford and Citigroup and a couple of OTCB stocks. NFEC and PKPL those ones not doing hot and the rest in Canadian stocks on the TSX. How is the weather where u live is it cold yet?
So lucky steve shorts and T-shirts...LOL I live in BC rain and more rain rolling fog and damp. Temperatures a bit cooler now but no snow yet. I don't think I would get into YASH for awhile until they get their act together. Looking at the market today very few stocks survived a lot of red on both sides of the border. Since year is almost to the end stocks should do better for next quarter. Still lots of earnings still to come for next month so gotta hold unto my hat. Hopefully commodities will hold steady and oil might take off big time, natural gas only if we have a cold winter, energy stocks a maybe rally and gold to hold just steady, mining and metals I think will rally up. China so far is taking over lots of commodities and companies and still gobbling all resources, financials and banks may turn around to the upside early next year. My predictions only..LOL
Still bad a sue is a sue and lawsuits means one thing to a stock going down in value until something is heard of the outcome. Too bad for YASH could have picked up if they had PR out of merger but I don't think that will be coming anytime soon. YASH will bleed down for awhile now.